The Parkinson’s Progression Marker Initiative (PPMI) is an observational, international study designed to establish biomarker defined cohorts and identify clinical, imaging, genetic and biospecimen Parkinson’s disease (PD) progression markers to accelerate disease modifying therapeutic trials. A total of 423 untreated PD, 196 Healthy Control (HC), 64 SWEDD (scans without evidence of dopaminergic deficit) subjects, and 65 Prodromal subjects (individuals with hyposmia or REM Sleep Behavior Disorder) were enrolled. PPMI is actively enrolling affected and unaffected individuals with genetic mutations in LRRK2, GBA, or SNCA through the end of 2018. For the most up to date enrollment numbers, please visit http://www.ppmi-info.org/study-design/study-cohorts/. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.
The health of the agricultural population has been previously explored, particularly in relation to the farming exposures and among professionally active individuals. However, few studies specifically focused on health and aging among elders retired from agriculture. Yet, this population faces the long-term effects of occupational exposures and multiple difficulties related to living and aging in rural area (limited access to shops, services, and practitioners). However, these difficulties may be counter-balanced by advantages related to healthier lifestyle, richer social support and better living environment. The general aim of the AMI cohort was to study health and aging in elderly farmers living in rural area through a multidisciplinary approach, with a main focus on dementia.
The study started in 2007, with two follow-up visits over 5 years. Baseline visits were conducted at home by a neuropsychologist then by a geriatrician for all cases suspected of dementia, for all subjects suspected of being demented. The 10-year visit is currently on going.
For the Esprit study, 1863 non-institutionalized persons aged 65 years and over were randomly recruited in 1999 from the Montpellier district electoral rolls, and re-examined 6-times at 2-3 yearly intervals. Objectives:
1) To determine current and lifetime prevalence as well as incidence of psychiatric disorder in the elderly;
2) to determine the risk factors for these disorders, their relative weight and interactions;
3) to study clinical heterogeneity;
4) to estimate the probability of transition towards a subsyndromic state or a given pathology;
5) to elaborate predictive etiological models.
i-Share (Internet-based Students HeAlth Research Enterprise) is a new open and prospective cohort on university students’ health. Participants are registered in the first years of study initially with the Universities of Bordeaux and Versailles-Saint-Quentin many many other French universities are now participating. Students are followed up with yearly assessments.
The study sets 2 main types of objectives:
1. Evaluate the frequency and impact of several diseases that may have immediate or short-term consequences on health and well-being (e.g. stress and depression, migraine, sexually transmitted infectious diseases, etc.).
2. Biomedical research objectives on the determinants of diseases. We have set up a cerebral MRI study and biobank on a sample of about 2000 participants including DNA and RNA.
The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. A total of 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.
The EVA study was a 9-year longitudinal study with 6 waves of follow-ups. During the two-year period 1991-1993 (EVA0), 1389 men and women born between 1922 and 1932 were recruited.
The aim is to investigate vascular ageing, decline in brain and cognitive function and associated factors with a longitudinal follow-up study. The secondary objective is to determine to role of biological factors linked with oxidative stress and brain ageing.
Inclusion criteria Subjects from both genders born between 1922 and 1932 (59 to 71 years old at enrolment), included in electoral registers in Nantes, can speak French and living in Nantes.
Last Update 21/09/2017
The EADC-PET project (EAPP, The European Alzheimer’s Disease Consortium PET project) is a spontaneous multicentric study (ProtocolDraftSep2008; ProtocolDraftFeb2009) involving at the moment five Centres in four Countries (CENTRES), belonging to the EADC consortium. It was launched during the EADC meeting in Amsterdam, during fall 2007, by Flavio Nobili (Genoa) who is the Principal Investigator.
The project aims at sharing FDG-PET, MRI, neuropsychological, genetic, EEG and clinical information of patients with amnestic Mild Cognitive Impairment (aMCI) and matched healthy controls. Information is uploaded in a safe FTP facility on the server of University of Genoa. Username and password have been provided to all participants. Use of data is regulated by a ‘Confidentiality Disclosure Agreement’ that can be downloaded from this web site (Confidential_Disclosure_Agreement). The Centres propose original studies by sending a formal proposal to all participants who can agree or disagree, or propose modifications/suggestions to the original proposal.
The objective is to follow-up aMCI patients with clinical and neuropsychological examinations to pick up conversion to Alzheimer’s dementia or to other forms of dementia. FDG-PET can be analyzed by means of several post-processing strategies to highlight glucose metabolic information and to identify the characteristics of what is today called ‘prodromal’ AD.
Last Update 21/09/2017
STROKOG is a consortium of longitudinal studies of cognitive disorders following stroke, TIA or small vessel disease. Developed under the auspices of VASCOG (Society for the Study of Vascular Cognitive and Behavioural Disorders), it is the first international effort to harmonise work on post-stroke dementia and is being led by CHeBA researchers.
The consortium brings together studies that have examined post-stroke or other high vascular risk cohorts longitudinally, with cognitive decline and dementia (including sub-types) as primary outcome variables. The included studies (N=27; total sample of more than 10,000 individuals, representing 17 countries) have rich neuropsychological and MRI data, and some recent studies (n=3) have included amyloid imaging in sub-samples. A number of studies have CSF and/or plasma available for biomarker studies, and participant enrolment in brain banks for neuropathology.
Last Update 21/09/2017
The CONSTANCES general-purpose cohort is intended to serve as an epidemiological research infrastructure accessible to the epidemiologic research community with a focus on chronic diseases and aging. CONSTANCES is designed as a randomly selected representative sample of French adults aged 18-69 years at inception; 200,000 subjects will be included over a five-year period. At inclusion, the selected subjects are invited to complete questionnaires and to attend a Health Screening Clinic (HSC) for a comprehensive health examination. A biobank will be set up. The follow-up includes a yearly self-administered questionnaire, and a periodic visit to an HSC. Social and health data are collected from the French national databases. Data collected for participants include social and demographic characteristics, socioeconomic status, life events, behaviors, and occupational factors. The health data cover a wide spectrum: self-reported health scales, reported prevalent and incident diseases, long-term chronic diseases and hospitalizations, sick-leaves, handicaps, limitations, disabilities and injuries, healthcare utilization and services provided, and causes of death. To take into account non-participation at inclusion and attrition throughout the longitudinal follow-up, a cohort of non-participants was set up and will be followed through the same national databases as participants.
Last update – 20/06/2017
In 2009, when it was launched, the Tempo cohort consisted of 1,103 people between the ages of 22 and 35 who had participated in a study on children and adolescents’ health between 1991 and 1999: “Les Enfants de Gazel”.
In 2011, Tempo cohort expanded to:
– include young people aged 18-25 years who have specific health situations and life situations
– increase the number of participants to study infrequent health problems.
In 2011 1,214 people were interviewed. In 2015, 783 people participated in the study and 533 participants returned a saliva collection kit. Saliva samples allow us to identify genetic markers that are associated with addictive behaviours (tobacco, alcohol and cannabis/CBD) in relation to characteristics of people’s lives.
In total 526 respondents responded at least three times, and 334 at least four times, giving us the opportunity to examine health trajectories over time.
Participants in the Tempo cohort were asked about their health, the situations they encountered in their daily lives, their work and family experiences.
Last update – 12/05/2017